Nivya George
Family · Jenkintown, PANPI 1275259772
Payments from drug & device makers
Across 139 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Scilex Pharmaceuticals Inc.$325
- Collegium Pharmaceutical, Inc.$280
- AbbVie$276
- Lilly USA, LLC$123
- Pfizer$103
- plus $373 from 8 others
What the payments were for
- Food & beverage$2,568100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 64 | $1,088 |
| Scilex Pharmaceuticals Inc. | 17 | $325 |
| Collegium Pharmaceutical, Inc. | 18 | $280 |
| AbbVie | 14 | $276 |
| Lilly USA, LLC | 5 | $123 |
| Pfizer | 4 | $103 |
| Merck | 5 | $93 |
| Protega Pharmaceutials Inc | 2 | $87 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Valinor Pharma, LLC | 2 | $47 |
| Orexo US, Inc. | 2 | $33 |
| Vertex | 1 | $25 |
| Almatica Pharma LLC | 1 | $22 |
| Indivior Inc. | 1 | $16 |
How this compares
$2,568 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 84 | $211,978 |
| OxycontinOxycodone Hcl | 103 | $95,173 |
| Xtampza ErOxycodone Myristate | 106 | $83,773 |
| Oxycodone Hcl | 737 | $20,908 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $19,879 |
| ZtlidoLidocaine | 15 | $16,839 |
| Buprenorphine | 45 | $15,837 |
| NucyntaTapentadol Hcl | 17 | $15,168 |
| LinzessLinaclotide | 23 | $11,399 |
| BelsomraSuvorexant | 25 | $10,904 |
| Emgality SyringeGalcanezumab-Gnlm | 11 | $7,753 |
| Morphine Sulfate ErMorphine Sulfate | 90 | $5,213 |
| Lidocaine | 42 | $4,231 |
| Gabapentin | 309 | $3,635 |
| EndocetOxycodone Hcl/Acetaminophen | 66 | $2,750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,088 | $211,97884 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta | $280 | $98,941123 claims |
| Indivior Inc.Suboxone | $16 | $19,87925 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $325 | $16,83915 claims |
| AbbVieLinzess | $276 | $11,39923 claims |
| MerckBelsomra | $93 | $10,90425 claims |
| Almatica Pharma LLCSertraline Hcl | $22 | $5417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.
Other family in Jenkintown
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.